Drug manufacturers have been left in a climate of anxious anticipation and a heightened state of uncertainty as the pharma industry waits to see if the president is bluffing.
The company is working with the CDMO partners in the U.K. and Spain to prepare for potential launch of MYR-101 for Canavan disease, pending regulatory approvals.
